Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.
The application of artificial intelligence methods to electronic patient records paves the way for large-scale analysis of multimodal data. Such population-wide data describing deep phenotypes…
Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.
Why the AQUILA trial is disappointing for patients and their loved ones
AbstractBACKGROUND AND AIMS. Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative stu
Discussing the tradeoffs in public-health decisions might help us make better choices, write Dr. Christopher Worsham and Dr. Anupam Jena.
Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations.…
Despite the scary headlines about genotoxicity, the answer is still probably no.
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
I hope that we can eventually take a deep breath, think, and return to how we managed things prior to the pandemic, except in cases…
Key Points. Air pollution exposure is common, and may increase risk of developing blood clots.Greater long-term exposure to air pollution (i.e., PM2.5, NOx
